MRI-based radiomics of sarcomas in the preclinical arm of a co-clinical trial

M. D. Holbrook; S. J. Blocker; Y. Mowery; A. Badea; Y. Qi; D. G. Kirsch; C. T. Badea

doi:10.1117/12.2549628

28 February 2020 MRI-based radiomics of sarcomas in the preclinical arm of a co-clinical trial

M. D. Holbrook, S. J. Blocker, Y. Mowery, A. Badea, Y. Qi, D. G. Kirsch, C. T. Badea

Proceedings Volume 11317, Medical Imaging 2020: Biomedical Applications in Molecular, Structural, and Functional Imaging; 1131711 (2020) https://doi.org/10.1117/12.2549628
Event: SPIE Medical Imaging, 2020, Houston, Texas, United States

Abstract

Radiomics provide an exciting approach to developing imaging biomarkers in the context of precision medicine. We focus on the preclinical arm of a co-clinical trial investigating synergy of immunotherapy combined with radiation therapy (RT) and surgical resection using a genetically engineered mouse model of sarcoma. Our protocol involves the acquisition of MRI data with T1, T2 and T1 with contrast agent. There are two MRI time points i.e. one day before RT (20Gy) and one week later. After the second MRI acquisition the primary tumor is surgically removed, and the mice are followed for up to 6 months to investigate for local recurrence or distant metastases. The tumor images are segmented using deep learning. We performed radiomics for the tumor, peritumoral rim and the combined tumor and peritumoral rim. Our first radiomics analysis was focused on determining features which are most indicative to the effects of RT. Our second analysis aimed to answer if radiomics features could predict primary tumor recurrence within this population. Top features were selected for training classifiers based on neural networks and support vector machines. Our results show that gray level radiomic features show that tumors often acquire more heterogeneous texture and that tumor volume increases one-week post RT. The results also suggest that radiomics features serve to indicate likelihood of primary tumor recurrence with the best predictive power in the combined tumor and peritumoral area in pre-RT data (AUC: 0.83). In conclusion, we have created a radiomics pipeline to serve in our current preclinical arm of the co-clinical trial.

Conference Presentation

Citation Download Citation

M. D. Holbrook, S. J. Blocker, Y. Mowery, A. Badea, Y. Qi, D. G. Kirsch, and C. T. Badea "MRI-based radiomics of sarcomas in the preclinical arm of a co-clinical trial", Proc. SPIE 11317, Medical Imaging 2020: Biomedical Applications in Molecular, Structural, and Functional Imaging, 1131711 (28 February 2020); https://doi.org/10.1117/12.2549628

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available